HIV/Aids drugs for developing world face threat of disruption
Financial Time - "Just four companies supply the bulk of antiretroviral medication to poorer countries. According to UNAids, the United Nations programme on HIV/Aids, 17m people received treatment for HIV infection with antiretroviral drugs (ARVs) in 2016. Of these, 13.9m lived in low and middle-income countries (LMICs).
Fifteen generic manufacturers supply more than 95 per cent of ARVs to LMICs, of which four supply the bulk — 83 per cent. In 2014, those four suppliers each provided about 20 per cent of the total volume, but since 2015, with new procurement policies among the main buyers, one company, Mylan, supplied more than 50 per cent, and three others, Hetero, Cipla and Aurobindo, provided 32-35 per cent between them. The remaining 11 each supply 2 per cent or less.